文献速递儿科影像技术与安全PETCT

儿童朗格汉斯细胞组织细胞增生症的18F-FDG PET/CT:与BRAFv600e突变及危险度分层的关系

18F-FDG PET/CT in pediatric langerhans cell histiocytosis: relation to BRAFv600e mutation and risk stratification.
PubMed 文献 · Eur J Radiol · 2025-08-13

回顾性分析114例初诊儿童朗格汉斯细胞组织细胞增生症的预处理18F-FDG PET/CT,PET/CT使47例(41.2%)患者疾病分层发生改变,最常见新增受累器官为淋巴结和胸腺。CRP升高与分期上调相关(OR 2.737),BRAFV600E突变组SUVmax较低(8.2±3.3 vs 10.8±4.9),SUVmax≤10.6、无胸腺受累及CRP≥15.0 mg/L与BRAFV600E突变显著相关,但置信区间宽需谨慎解读。

要点

  • PET/CT使41.2%(47/114)患儿疾病分层改变,最常见新增受累为淋巴结和胸腺。
  • CRP升高者更易分期上调(OR 2.737,95%CI 1.193-6.276,p=0.017)。
  • BRAFV600E突变组SUVmax较低(8.2±3.3 vs 10.8±4.9,p=0.019)。

核心结论

  • PET/CT可发现约40%患者的骨外病变,尤其在CRP升高者中;18F-FDG PET/CT表现与BRAFV600E突变状态显著相关,但置信区间宽需谨慎解读。

研究设计与样本

  • 回顾性分析114例新诊断儿童朗格汉斯细胞组织细胞增生症的预处理18F-FDG PET/CT,探讨影像表现与临床病理参数的关系。

关键影像表现/征象

  • LCH病灶在CRP升高患者中SUVmax显著高于CRP正常者(10.2±4.7 vs 7.3±3.6,p=0.001)。
  • BRAFV600E突变患者SUVmax低于未突变者(8.2±3.3 vs 10.8±4.9,p=0.019)。
  • PET/CT最常见新增检出器官为淋巴结和胸腺。

诊断标准与关键数值

  • SUVmax≤10.6与BRAFV600E突变相关(OR 6.868,95%CI 1.751-26.946,p=0.006)。
  • 无胸腺受累与BRAFV600E突变相关(OR 11.849,95%CI 1.907-73.635,p=0.008)。
  • CRP≥15.0 mg/L与BRAFV600E突变相关(OR 8.062,95%CI 1.538-42.263,p=0.014)。
  • CRP升高与分期上调相关(OR 2.737,95%CI 1.193-6.276,p=0.017)。

局限性

  • 原文指出置信区间宽,需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: BRAFV600E correlates with high-risk features and poor response to chemotherapy in pediatric Langerhans cell histiocytosis (LCH). This study aimed to evaluate the role of 18F-FDG PET/CT in risk stratification and to explore the relationship between 18F-FDG uptake and BRAFV600E mutation in LCH.

METHODS: Pretreatment 18F-FDG PET/CT scans from 114 newly diagnosed pediatric LCH were retrospectively analyzed. The associations between imaging findings and clinico-pathological parameters were investigated.

RESULTS: PET/CT imaging led to a change of disease stratification in 47 (41.2 %) patients. The most common additional organs detected by PET/CT were lymph nodes and thymus. Elevated C-reactive protein (CRP) levels were associated with upstaging [Odds ratio (OR): 2.737, 95 % confidence interval (CI): 1.193-6.276, p = 0.017]. LCH lesions showed significantly higher SUVmax in patients with elevated CRP levels compared to those with normal levels (10.2 ± 4.7 vs. 7.3 ± 3.6, p = 0.001). BRAFV600E status was tested in 70 patients. Lower 18F-FDG uptake (SUVmax: 8.2 ± 3.3 vs. 10.8 ± 4.9, p = 0.019) was observed in mutated-BRAFV600E. Multivariate logistic regression analysis revealed that SUVmax ≤ 10.6 (OR: 6.868, 95 % CI: 1.751-26.946, p = 0.006), absence of thymus involvement (OR: 11.849, 95 %CI: 1.907-73.635, p = 0.008) and CRP ≥ 15.0 mg/L (OR: 8.062, 95 % CI: 1.538-42.263, p = 0.014) significantly correlated with BRAFV600E mutation.

CONCLUSIONS: PET/CT identifies extra-osseous diseases in about 40% of patients, especially those with elevated CRP levels. Moreover, 18F-FDG PET/CT findings were significantly associated with BRAFV600E mutation status, although wide CIs warrant cautious interpretation.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Ji X, Li C, Gou J, et al. 18F-FDG PET/CT in pediatric langerhans cell histiocytosis: relation to BRAFv600e mutation and risk stratification. Eur J Radiol. 2025. PMID: 40819625. doi:10.1016/j.ejrad.2025.112361

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。